Salinomycin sodium salt
(Synonyms: 盐霉素钠; Salinomycin sodium; Sodium salinomycin) 目录号 : GC18107Salinomycin sodium salt是一种由Streptomyces albus发酵产生的大环聚醚离子载体抗生素。
Cas No.:55721-31-8
Sample solution is provided at 25 µL, 10mM.
Salinomycin sodium salt is a macrocyclic polyether ionophore antibiotic produced by the fermentation of Streptomyces albus[1-2]. Salinomycin sodium salt is used in research for the prevention and treatment of coccidiosis in livestock and poultry, as well as for anticancer studies[3-4].
In vitro, Salinomycin sodium salt (0.1–40μM) was combined with Doxorubicin to treat feline injection-site sarcoma C10 cells and squamous cell carcinoma SCCF1 cells for 48 hours. Salinomycin sodium salt significantly enhanced the cytotoxicity of doxorubicin, demonstrating a synergistic effect in both C10 and SCCF1 cells[5]. Salinomycin sodium salt (1μM) was used to treat human melanoma SK-Mel-19 cells for 24 hours. Salinomycin sodium salt induced a decrease in mitochondrial membrane potential and endoplasmic reticulum stress by inhibiting autophagic flux, leading to autophagic cell death[6].
In vivo, Salinomycin sodium salt (20mg/kg/day) was orally administered to Cd-exposed mice starting 15 days after Cd exposure, once daily for 14 consecutive days. Salinomycin sodium salt significantly reduced Cd accumulation in the liver and kidneys, restored hepatic and renal function markers, and alleviated histopathological damage in the liver[7]. Salinomycin sodium salt (16mg/kg/day) was orally administered to Pb-exposed mice starting 15 days after Pb exposure, once daily for 14 consecutive days. Salinomycin sodium salt significantly reduced abnormal elevations of magnesium and phosphorus in the brain and mitigated Pb-induced neuronal necrosis and histopathological changes in brain tissue[8].
References:
[1] Qi D, Liu Y, Li J, et al. Salinomycin as a potent anticancer stem cell agent: State of the art and future directions. Med Res Rev. 2022 May;42(3):1037-1063.
[2] Dewangan J, Srivastava S, Rath SK. Salinomycin: A new paradigm in cancer therapy. Tumour Biol. 2017 Mar;39(3):1010428317695035.
[3] Jiang J, Li H, Qaed E, et al. Salinomycin, as an autophagy modulator-- a new avenue to anticancer: a review. J Exp Clin Cancer Res. 2018 Feb 13;37(1):26.
[4] Antoszczak M, Huczyński A. Anticancer Activity of Polyether Ionophore-Salinomycin. Anticancer Agents Med Chem. 2015;15(5):575-91.
[5] Borlle L, Dergham A, Wund Z, et al. Salinomycin decreases feline sarcoma and carcinoma cell viability when combined with doxorubicin. BMC Vet Res. 2019 Jan 24;15(1):36.
[6] Liu Y, Hao Y, Li Y, et al. Salinomycin induces autophagic cell death in salinomycin-sensitive melanoma cells through inhibition of autophagic flux. Sci Rep. 2020 Oct 28;10(1):18515.
[7] Kamenova K, Gluhcheva Y, Vladov I, et al. Ameliorative effect of the anticancer agent salinomycin on cadmium-induced hepatotoxicity and renal dysfunction in mice. Environ Sci Pollut Res Int. 2018 Feb;25(4):3616-3627.
[8] Petrova E, Gluhcheva Y, Pavlova E, et al. Effects of Salinomycin and Deferiprone on Lead-Induced Changes in the Mouse Brain. Int J Mol Sci. 2023 Feb 2;24(3):2871.
Salinomycin sodium salt是一种由Streptomyces albus发酵产生的大环聚醚离子载体抗生素 [1-2]。Salinomycin sodium salt可用于畜禽养殖中防治球虫病以及抗癌的相关研究[3-4]。
在体外,Salinomycin sodium salt(0.1-40μM)联合多柔比星处理猫注射部位肉瘤细胞C10和鳞状细胞癌SCCF1细胞48小时,Salinomycin sodium salt显著增强多柔比星的细胞毒性,在C10和SCCF1细胞中表现为协同效应 [5]。Salinomycin sodium salt(1μM)处理人黑色素瘤SK-Mel-19细胞24小时,Salinomycin sodium salt通过抑制自噬流诱导线粒体膜电位下降和内质网应激,导致自噬性细胞死亡[6]。
在体内,Salinomycin sodium salt(20mg/kg/day)口服处理Cd暴露小鼠(从Cd暴露后第15天开始,连续14天),Salinomycin sodium salt显著降低肝脏和肾脏中的Cd蓄积,恢复肝肾功能指标,并改善肝组织病理学损伤[7]。Salinomycin sodium salt(16mg/kg/day)口服处理Pb暴露小鼠(从Pb暴露后第15天开始,连续14天),Salinomycin sodium salt显著降低脑组织中镁和磷的异常升高,并减轻Pb诱导的神经元坏死和脑组织病理学变化[8]。
| Cell experiment [1]: | |
Cell lines | B4 and C10 feline injection-site sarcoma cells, SCCF1 feline oral squamous cell carcinoma cells |
Preparation Method | Cells were maintained in DMEM supplemented with 10–20% FBS and treated with Salinomycin sodium salt (0.1–40μM) and/or Doxorubicin (0.092–138μM) for 48 hours. |
Reaction Conditions | 0.1–40μM; 48h. |
Applications | Salinomycin sodium salt significantly reduced cell viability in a dose-dependent manner. When combined with Doxorubicin, Salinomycin sodium salt (5μM) enhanced cytotoxicity, showing synergistic effects and reducing viability at clinically achievable Doxorubicin concentrations in C10 and SCCF1 cells. |
| Animal experiment [2]: | |
Animal models | ICR mice |
Preparation Method | Mice were orally administered Cd(II) acetate (20mg/kg) once daily for 14 days, followed by treatment with Salinomycin sodium salt (20mg/kg) orally once daily for an additional 14 days. Mice were sacrificed on day 29 for organ and serum analysis. |
Dosage form | 20mg/kg; p.o.; Daily administration for 14 days. |
Applications | Salinomycin sodium salt significantly reduced cadmium accumulation in the liver and kidneys, restored hepatic and renal functional markers (ALT, ALP, GGT, creatinine) to normal levels, ameliorated cadmium-induced histopathological damage in liver and kidney tissues, and normalized endogenous essential metal ion (Cu, Zn, Fe) concentrations. |
References: | |
| Cas No. | 55721-31-8 | SDF | |
| 别名 | 盐霉素钠; Salinomycin sodium; Sodium salinomycin | ||
| 化学名 | sodium;2-[6-[6-[3-(5-ethyl-5-hydroxy-6-methyloxan-2-yl)-15-hydroxy-3,10,12-trimethyl-4,6,8-trioxadispiro[4.1.57.35]pentadec-13-en-9-yl]-3-hydroxy-4-methyl-5-oxooctan-2-yl]-5-methyloxan-2-yl]butanoate | ||
| Canonical SMILES | CCC(C1CCC(C(O1)C(C)C(C(C)C(=O)C(CC)C2C(CC(C3(O2)C=CC(C4(O3)CCC(O4)(C)C5CCC(C(O5)C)(CC)O)O)C)C)O)C)C(=O)O.[Na] | ||
| 分子式 | C42H69NaO11 | 分子量 | 773.99 |
| 溶解度 | DMF: 20 mg/ml,DMF:PBS (pH 7.2) (1:4): 0.2 mg/ml,DMSO: 5 mg/ml,Ethanol: 10 mg/ml | 储存条件 | Store at -20°C, stored under nitrogen |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
![]() |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.292 mL | 6.46 mL | 12.9201 mL |
| 5 mM | 258.4 μL | 1.292 mL | 2.584 mL |
| 10 mM | 129.2 μL | 646 μL | 1.292 mL |
| 第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
| 给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
| 第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
















